drugset / Trial / NCT03869944
Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV
Phase 2
Unknown
97 enrolled
ANRS, Emerging Infectious Diseases
Centre Muraz · collabInstitut National de la Santé Et de la Recherche Médicale, France · collab
NaSingle-groupOpen-labelPrevention
Summary
The second visit of the Expanded Programme of Immunization when the child is 2 months old (EPI-2) represents a unique opportunity to link the EPI and PMTCT programmes and to introduce preventive and therapeutic rescue interventions in order to 1) Assess the efficacy of the PMTCT cascade up to 2 months postpartum; 2) Allow at least 80% of HIV-1-infected infants identified at the second EPI visit who were not involved in HIV care to initiate ARVs at the earliest, but no later than 2 months after confirmation of HIV diagnosis; 3) Reduce HIV-1 transmission to less than 3% between 2 and 12 months among exposed children who completed the second EPI visit
Timeline
- Start
- 2019-12-04
- Primary completion
- 2022-03
- Completion
- 2022-03
Publications
- Background Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Marechal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskar T, Van de Perre P; ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19.
- Mennecier A, Sakana BLD, D'Ottavi M, Tassembedo S, Moles JP, Kania D, Taofiki AO, Kadeba FE, Diallo I, Eymard-Duvernay S, Meda N, Mosqueira B, Fao P, Nagot N; PREVENIR-PEV Study Group; Vande Perre P. An optimized strategy triggered at the 2nd immunization visit to prevent HIV acquisition by breastfeeding: a phase 2 trial in Burkina Faso (PREVENIR-PEV). BMC Infect Dis. 2024 Sep 20;24(1):1014. doi: 10.1186/s12879-024-09910-z.
- Mennecier A, Kankasa C, Fao P, Moles JP, Eymard-Duvernay S, Mwiya M, Kania D, Chunda-Liyoka C, Sakana L, Rutagwera D, Tassembedo S, Wilfred-Tonga MM, Mosqueira B, Tylleskar T, Nagot N, Van de Perre P; ANRS 12397 Study group. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso. Contemp Clin Trials. 2021 Jun;105:106402. doi: 10.1016/j.cct.2021.106402. Epub 2021 Apr 17.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | 7.5 mg | Oral |
| Subject | Lamivudine | Other / unclassified | 25 mg | Oral |
| Subject | Lamivudine | Other / unclassified | 50 mg | Oral |
Indications
No indication recorded.